British oncologists back biosimilar mAbs to treat cancer

Home/Policies & Legislation | Posted 03/03/2017 post-comment0 Post your comment

The British Oncology Pharmacy Association (BOPA) announced on 7 February 2017 the publication of its position statement and implementation guidelines on Biosimilar Monoclonal Antibodies.

Cancer image015

In its guideline document BOPA states that ‘oncology pharmacy teams are key to ensuring the safe, successful and timely adoption of biosimilar monoclonal antibodies (mAbs)’.

BOPA’s position is that ‘biosimilar mAbs are therapeutically equivalent to the originator molecules and can and should be used for all commissioned indications, provided pharmacovigilance safeguards are in place, e.g. branded prescribing.

Although BOPA acknowledges that ‘biosimilar mAbs cannot be automatically substituted’ they state that ‘switching from originator to biosimilar (or biosimilar to biosimilar) is acceptable and can be recommended as part of a medicines optimisation strategy’. They also believe that ‘oncology pharmacy teams have a key role in helping clinicians initiate or switch patients to biosimilar mAbs, either by directly supporting clinicians when seeing patients in clinic or indirectly by counselling patients in pharmacy, on wards or chemotherapy day units’.

The group adds that ‘oncology pharmacy teams are key to ensuring pharmacovigilance monitoring is in place to ensuring all biosimilars are prescribed by brand and batch numbers are tracked’. They add that ‘all patients switched from originator to biosimilar, or between biosimilars should be monitored and that the biosimilars SmPC (Summary of Product Characteristics) guidance on administration rates should be followed’. This they say ‘will ensure that the evidence base for safe switching is increased.’

BOPA also believes that ‘biological medicines in general are safe and well tolerated, with the potential for immunogenicity the main safety concern and that adverse reactions are likely to be batch related and not product related’.

In addition, the group states that ‘BOPA believes that the savings achieved by rapid adoption of biosimilar mAbs are an opportunity to safeguard NHS (National Health Service) budgets’ and ‘ensure that new innovative cancer medicines are affordable’. This they say will benefit patients and clinicians as well as significantly reduce NHS expenditure.

Related article
European IBD specialists support switching to biosimilars

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2017 Pro Pharma Communications International. All Rights Reserved.

Source: BOPA

comment icon Comments (0)
Post your comment
Related content
PDUFA VI: FDA could promote generics competition
47 MD001813
Home/Policies & Legislation Posted 29/07/2022
House bill passes FDA funding fees but conflicts with Senate bill
User Fee V13H23
Home/Policies & Legislation Posted 15/07/2022
US Senate clarifies status of interchangeable biosimilar exclusivity
Interchangeability V18K30
Home/Policies & Legislation Posted 27/05/2022
Nomenclature of biologicals and biosimilars in Peru
02 AA010638
Home/Policies & Legislation Posted 20/05/2022
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010